Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02265588
Other study ID # NL49147.078.14
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date August 24, 2017

Study information

Verified date July 2022
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The presented study aims to reduce symptoms of depression and anxiety in adolescents with inflammatory bowel disease and increased symptoms of anxiety and depression by using the disease specific CBT program (PASCET-PI)in order to improve quality of life and to improve the clinical course of disease.


Description:

1. Objective: The primary objective is to determine the efficacy of a disease specific cognitive behavioral therapy program in adolescents with IBD and increased symptoms of depression or anxiety on reducing symptoms of depression. Secondary objectives are to assess the effect of the CBT program on a) the clinical course of disease b) reducing symptoms of anxiety, and c) improving quality of life. We also aim to identify psychosocial and medical factors that predict or moderate the treatment response to CBT in adolescent with IBD. 2. Study design: The presented study is a multicenter randomized controlled trial (RCT), involving CBT versus care as usual (CAU), in young IBD patients with increased symptoms of self-reported depression or anxiety. There will be three follow-up moments, after 3 months or after the intervention and after 6 and 12 months. 3. Study population: Patients with IBD between 10-25 years and increased symptoms of depression or anxiety. We aim to include 100 patients, from which 50 patients will be randomized to the treatment condition (CBT and CAU) and 50 to the control group (CAU). 4. Intervention: A disease specific CBT program called PASCET-PI. The control group (CAU),will receive routine medical treatment (thus no additional psychosocial intervention) and will maintain their regular follow up visits at the gastroenterologist every 3 months. 5. Main study endpoints: Main outcome is reduction in symptoms of depression. Important secondary outcomes are the presence of clinical relapse and reduction of symptoms of anxiety. Other secondary outcomes, amongst others, are IBD activity scores, quality of life, psychosocial functioning, and adherence to medical treatment. 6. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: At first, patients with IBD 10 -25 years of age will be screened for symptoms of depression and anxiety at T1. Patients with increased symptoms of self-reported depression or anxiety (scoring above an age and gender specific cut-off score for increased depressive or anxiety symptoms) are asked to participate in the RCT. For all included patients, 4 study visits will take place, these will be combined with regular checkup visits at the gastroenterologist. Questionnaires will need to be filled in online, taking approximately 1.5 hour per assessment for patients and approximately 1 hour per assessment for parents. At baseline a psychiatric assessment interview will be executed by an independent research clinical psychologist by phone (20 minutes). The same research clinical psychologist will conduct a short psychiatric assessment interview at the follow up visits 10minutes). At baseline and after 3 months blood samples (when patients undergo routine venous punctures) will be drawn. For patients in the CBT group, 13 sessions (6 outpatient sessions, 7 by phone) and three parental sessions will take place in a hospital close to their home. Our study population consists of adolescents and young adults with IBD, as this is a specific group with high reported symptoms of depression and anxiety, therefore they will most likely benefit from the intervention. The risks associated with participation can be considered negligible and the burden minimal. For the time investment of completing the questionnaires participants will receive an incentive of 25 euro after the final assessment, which will be communicated at the start.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date August 24, 2017
Est. primary completion date October 1, 2016
Accepts healthy volunteers No
Gender All
Age group 10 Years to 20 Years
Eligibility Inclusion Criteria: - Patients between 10-25 years with diagnosed IBD - Informed consent or assent by patients and (if necessary) parents Exclusion Criteria: - IBD patients with parental report of mental retardation - IBD patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for depression or anxiety - No mastery of the Dutch language - IBD patients with diagnosed: Bipolar disorder, Schizophrenia/psychotic disorder, Autism spectrum disorders, Obsessive-compulsive disorder, Posttraumatic stress disorder/Acute stress disorder, or Substance use disorder - Physician reported substance abuse (alcohol, drugs) in the past month - Clinician reported Selective mutism - IBD patients already participating in an (psychological of psychopharmacological) intervention study - IBD patients who received 8 sessions of manualized cognitive behavioral therapy last year - current psychological treatment

Study Design


Intervention

Behavioral:
Cognitive behavioral therapy
A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.

Locations

Country Name City State
Netherlands Erasmus Medical Center Rotterdam Nederland

Sponsors (7)

Lead Sponsor Collaborator
Erasmus Medical Center Albert Schweitzer Hospital, Amphia Hospital, Haga Hospital, Leiden University Medical Center, Maasstad Hospital, Reinier de Graaf Groep

Country where clinical trial is conducted

Netherlands, 

References & Publications (2)

Szigethy E, Kenney E, Carpenter J, Hardy DM, Fairclough D, Bousvaros A, Keljo D, Weisz J, Beardslee WR, Noll R, DeMASO DR. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 2007 Oct;46(10):1290-1298. doi: 10.1097/chi.0b013e3180f6341f. — View Citation

Thompson RD, Craig A, Crawford EA, Fairclough D, Gonzalez-Heydrich J, Bousvaros A, Noll RB, DeMaso DR, Szigethy E. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep;19(3):329-37. doi: 10.1007/s10880-012-9301-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Disease perception (change from baseline) Assesses by the Brief Illness Perceptions Questionnaire (B-IPQ) 12 weeks
Other Cognitive coping styles (change from baseline) Assesses by the Cognitive Emotion Regulation Questionnaire (CERQ) 12 weeks
Other Quality of sleep (change from baseline) Assesses by the Sleep Self-Report (SSR) (10-20 years) PSQI: Pittsburgh Sleep Quality Index (21-25 year) 12 weeks
Other Demographic factors Assesses by the Rotterdam's quality of life interview 12 weeks
Other Parental anxiety and depression Assesses by the Depression, Anxiety and Stress Scale (DASS-21) 12 weeks
Other Life Events Assesses by the Life events questionnaire from CERQ 12 weeks
Other Family Functioning (change from baseline) Assesses by the Family Assessment Device (FAD) 12 weeks
Other Disease phenotypes Assessed by the Paris Classification 52 weeks
Other Treatment Strategy The treatment strategy, type and dosage of medication will be extracted from the medical file and report of the treating physician. 52 weeks
Other White blood cell RNA expression profiles (change from baseline) Assessing immune status is done by analyzing gene expression profiles in peripheral blood leukocytes. This will be performed 12 weeks
Other Immunological activity in peripheral blood mononuclear cells (PBMC) A blood sample will be taken in all patients included within the Erasmus MC for determination of responsiveness of peripheral blood lymphocytes before and directly after the intervention 12 weeks
Other Irritable bowel syndrome -like symptoms Assessed by the ROME III diagnostic criteria for IBS in pediatric IBD patients 12 months
Primary Reduction in symptoms of depression (change from baseline) Measured by the Child Depression Inventory (CDI (10-17 years), Beck Depression Inventory (BDI; 18-25 years) and severity rating (interview): the Children's Depression Rating Scale (CDRS;10-12 years) and Adolescent Depression Rating Scale(ADRS;13-20 years), HAM-D: Hamilton Depression Rating Scale (21-25 year) 12 weeks and 52 weeks
Secondary Reduction in symptoms of anxiety (change from baseline) Measured by SCARED-NL: Screen for Anxiety Related Emotional Disorders (10-20 years), Hospital Anxiety and Depression Scale (HADS; 21-25 year) and severity rating by Pediatrix Anxiety Rating Scale (PARS) (10-20 years) ,Hamilton Anxiety Rating (HAM-A)(21-25 year) 12 weeks and 52 weeks
Secondary General Quality of Life Assessed by the Child Health Related Quality of Life (TACQOL) (10-15 years) Adult Health Related Quality of Life (TAAQOL, 16-25 years) 12 weeks and 52 weeks
Secondary Social Skills Assessed by Social Skills Rating System (SSRS) (10-20years) Novotni SSC: Social Skills Checklist (21-25 year) 12 weeks
Secondary Social competence Assessed by Youth Self Report (YSR) / Adult Self Report (ASR) 12 weeks
Secondary Disease specific quality of life Assessed by the IMPACT-III-NL (10-20years) IBDQ: Inflammatory Bowel Disease Questionnaire (21-25 year) 12 weeks and 52 weeks
Secondary Disease Activity Assessed by the Pediatric Ulcerative Colitis Activity Index (PUCAI) (10-20 years) Pediatric Crohn's Disease Activity Index (PCDAI) (10-20 years) CDAI: Crohn's Disease Activity Index (21-25 years) Partial Mayo Score (21-25 years) Physician Global Assessment (PGA) 52 weeks
Secondary Clinical relapse (number of flares) 10-20 Years: Relapse for CD is defined as PCDAI>30 or an increase of>15 points and intensification of medical treatment.
Relapse for UC is defined as PUCAI > 34 or an increase of =20 points for UC and intensification of medical treatment.
21-25 years: Partial Mayo score of 3 or higher with intensification of medical treatment Or CDAI= 150 and an increase in baseline CDAI score of = 70 points and intensification of medical treatment
52 weeks
Secondary Maintaining remission Remission is defined as PCDAI < 10 for CD and PUCAI < 10 for UC. CDAI < 150 and Mayo score =2 with no individual subscore > 1 52 weeks
Secondary Medication Usage (change from baseline) Type and dosage of medication 52 weeks
Secondary Necessity of surgical intervention Description of type and extent of surgical intervention 52 weeks
Secondary Adherence to therapy (change from baseline) Assessed by the Morisky Medical Adherence Scale (MASS-8) 52 weeks
Secondary Health care utilization (change from baseline) Assessed by standardized items derived from the questionnaires and Report of the treating physician. 52 weeks
Secondary Inflammatory markers Inflammatory markers will be measured at all time points (baseline and after 3,6,12 months) Inflammatory markers like BSE, CRP, faecal calprotectin baseline and 12, 24 and 52 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A